GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia

Area of Science:

• Metabolic Bone Disease
• Endocrinology
• Pharmacology

Background:

• Increased fat mass is linked to bone deterioration.
• Glucagon-like peptide 1 (GLP-1) and exendin-4 (Ex-4) are lipid-lowering peptides with potential osteogenic effects in diabetic conditions.
• Hyperlipidemia and hypercaloric diets negatively impact bone mass and structure.

Purpose of the Study:

• To investigate the effects of GLP-1 and Ex-4 on bone remodeling markers, bone mass, and bone structure in hyperlipidemic rats.
• To evaluate the efficacy of these peptides in reversing fat-induced bone alterations.

Main Methods:

• Wistar rats were fed a hyperlipidemic diet for 35 days.
• Subcutaneous administration of GLP-1, Ex-4, or saline was performed via continuous infusion for 3 days.
• Bone mass, structure, and remodeling markers in tibiae, femurs, and vertebrae were assessed post-treatment.

Main Results:

• Hyperlipidemic rats exhibited osteopenia, hyperglycemia, hypertriglyceridemia, and hypercholesterolemia.
• GLP-1 and Ex-4 administration reduced plasma glucose, triglycerides, and total cholesterol.
• Both peptides increased osteocalcin gene expression and the osteoprotegerin (OPG)/receptor activator of NF-κB ligand (RANKL) ratio, reversing bone mass reduction and improving vertebral bone structure.

Conclusions:

• GLP-1 and Ex-4 are similarly effective in reversing bone alterations in a hyperlipidemic rat model.
• These findings highlight the potential of GLP-1 and Ex-4 in managing bone complications associated with metabolic disorders.
• The hyperlipidemic rat model is valuable for studying fat-bone relationships.